Holstege, Henne

Alzheimer's disease

Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 5,465

New insights into the genetic etiology of Alzheimer’s disease and related dementias

Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 2,498

A meta-analysis of genome-wide association studies identifies multiple longevity genes

Deelen, J., Evans, D. S., Arking, D. E., Tesi, N., Nygaard, M., Liu, X., Wojczynski, M. K., Biggs, M. L., van der Spek, A., Atzmon, G., et al. (2019) · Nature Communications

Genetic Associations and EpidemiologyGenetics, Aging, and Longevity in Model Organisms

Cited by 370

Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

de Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I. E., Pedersen, N. L., Stringa, N., Zettergren, A., Hernández, I., et al. (2021) · Nature Communications

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 324

Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease

Holstege, H., Hulsman, M., Charbonnier, C., Grenier-Boley, B., Quenez, O., Grozeva, D., van Rooij, J. G. J., Sims, R., Ahmad, S., Amin, N., et al. (2022) · Nature Genetics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 226

Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis

Holstege, H., Pfeiffer, W., Sie, D., Hulsman, M., Nicholas, T. J., Lee, C. C., Ross, T., Lin, J., Miller, M. A., Ylstra, B., et al. (2014) · Genome Research

Cancer Genomics and DiagnosticsAcute Myeloid Leukemia Research

Cited by 152

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Jansen, I. E., van der Lee, S. J., Gomez-Fonseca, D., de Rojas, I., Dalmasso, M. C., Grenier-Boley, B., Zettergren, A., Mishra, A., Ali, M., Andrade, V., et al. (2022) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 132

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

DESGESCO (Dementia Genetics Spanish Consortium), E. (. D. E. D. B., van der Lee, S. J., biobank), E. (. D. E. D., IFGC (International FTD-Genomics Consortium), I. (. I. P. D. G. C., IPDGC (The International Parkinson Disease Genomics Consortium), Dementia), R.-F. (. A. M. F. I. F.-T., (NBB), N. B. B., The GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Conway, O. J., Jansen, I., et al. (2019) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 120

Genome-wide significant risk factors for Alzheimer’s disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment

Lacour, A., Espinosa, A., Louwersheimer, E., Heilmann, S., Hernández, I., Wolfsgruber, S., Fernández, V, Wagner, H., Rosende-Roca, M., Mauleón, A., et al. (2017) · Molecular Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 101

Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease

Le Guen, Y., Belloy, M. E., Grenier-Boley, B., de Rojas, I., Castillo-Morales, A., Jansen, I., Nicolas, A., Bellenguez, C., Dalmasso, C., Küçükali, F., et al. (2022) · JAMA Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 93

Immune response and endocytosis pathways are associated with the resilience against Alzheimer’s disease

Tesi, N., van der Lee, S. J., Hulsman, M., Jansen, I. E., Stringa, N., van Schoor, N. M., Scheltens, P., van der Flier, W. M., Huisman, M., Reinders, M. J. T., et al. (2020) · Translational Psychiatry

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 67

Centenarian controls increase variant effect sizes by an average twofold in an extreme case–extreme control analysis of Alzheimer’s disease

Tesi, N., van der Lee, S. J., Hulsman, M., Jansen, I. E., Stringa, N., van Schoor, N., Meijers-Heijboer, H., Huisman, M., Scheltens, P., Reinders, M. J. T., et al. (2019) · European Journal of Human Genetics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 65

PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment

(ADNI), A. D. N. I., Kleineidam, L., Chouraki, V., Próchnicki, T., van der Lee, S. J., Madrid-Márquez, L., Wagner-Thelen, H., Karaca, I., Weinhold, L., Wolfsgruber, S., et al. (2020) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 62

Cognitively healthy centenarians are genetically protected against Alzheimer's disease

Tesi, N., van der Lee, S., Hulsman, M., van Schoor, N. M., Huisman, M., Pijnenburg, Y., van der Flier, W. M., Reinders, M., & Holstege, H. (2024) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 52

SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease

Ramirez, A., van der Flier, W. M., Herold, C., Ramonet, D., Heilmann, S., Lewczuk, P., Popp, J., Lacour, A., Drichel, D., Louwersheimer, E., et al. (2014) · Human Molecular Genetics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 49

Resilience and resistance to the accumulation of amyloid plaques and neurofibrillary tangles in centenarians: An age‐continuous perspective

Zhang, M., Ganz, A. B., Rohde, S., Rozemuller, A. J. M., Bank, N. B., Reinders, M. J. T., Scheltens, P., Hulsman, M., Hoozemans, J. J. M., & Holstege, H. (2023) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 43

Common variants in Alzheimer’s disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores

de Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I., Pedersen, N. L., Stringa, N., Zettergren, A., Hernández, I., et al. (2019) · medRxiv

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 28

Risk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score

Ebenau, J. L., van der Lee, S. J., Hulsman, M., Tesi, N., Jansen, I. E., Verberk, I. M. W., van Leeuwenstijn, M., Teunissen, C. E., Barkhof, F., Prins, N. D., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 26

TREM2 risk variants and associated endophenotypes in alzheimer’s disease

Dijkstra, J. I. R., Vermunt, L., Venkatraghavan, V., Ozhegov, G., Coomans, E. M., Ossenkoppele, R., van de Giessen, E., Hulsman, M., de Geus, C. M., van der Flier, W. M., et al. (2025) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 18

Carriers of the p.P522R variant in PLCγ2 have a slightly more responsive immune system

Diks, A. M., Teodosio, C., de Mooij, B., Groenland, R. J., Naber, B. A. E., de Laat, I. F., Vloemans, S. A., Rohde, S., de Jonge, M. I., Lorenz, L., et al. (2023) · Molecular Neurodegeneration

Immune responses and vaccinationsImmunodeficiency and Autoimmune Disorders

Cited by 14

Large-scale cerebrospinal fluid proteomic analysis in Alzheimer’s disease patients reveals five molecular subtypes with distinct genetic risk profiles

Tijms, B. M., Vromen, E. M., Mjaavatten, O., Holstege, H., Reus, L. M., van der Lee, S., Wesenhagen, K. E., Lorenzini, L., Vermunt, L., Venkatraghavan, V., et al. (2023) · medRxiv

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 10

Consensus meta-analysis of genome-wide association studies for Alzheimer’s disease and related dementias

EADB, Bellenguez, C., Castillo Morales, A., Amin, N., van der Lee, S. J., Muntaner, M., Parveen, K., Küçükali, F., Grenier-Boley, B., Heikkinen, S., et al. (2026) · Nature Genetics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 7

Non-microglial downregulation of PLCG2 impairs synaptic function and elicits Alzheimer disease-related hallmarks

Coulon, A., Rabiller, F., Takalo, M., Roy, A., Pelletier, A., Martiskainen, H., Siedlecki-Wullich, D., Lannette-Weimann, N., Majerníková, N., Grenon, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory)

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 3

PLCG2 downregulation impairs synaptic function and increases Alzheimer’s disease hallmarks in neuronal cultures

Coulon, A., Rabiller, F., Takalo, M., Roy, A., Pelletier, A., Martiskainen, H., Siedlecki-Wullich, D., Lannette-Weimann, N., Majerníková, N., Grenon, A., et al. (2026) · Nature Genetics

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 1